Search Results - "Kil LP"

Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis.

Authors: Lambe J Fox RJ

Source: Drugs [Drugs] 2026 Jul; Vol. 86 (7), pp. 989-1012. Date of Electronic Publication: 2026 May 13.

Publication Type: Journal Article; Review

Journal Info: Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 7600076 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1179-1950 (Electronic) Linking ISSN: 00126667 NLM ISO Abbreviation: Drugs Subsets: MEDLINE

Quantitative modeling of signaling in aggressive B cell lymphoma unveils conserved core network.

Authors: Klinger, Bertram Rausch, Isabel Sieber, Anja et al.

Source: PLoS Computational Biology. 10/01/2024, Vol. 20 Issue 10, p1-27. 27p.

Mitigating ibrutinib‐induced ventricular arrhythmia and cardiac dysfunction with metformin.

Authors: Li, Pengsha Liu, Daiqi Gao, Pan et al.

Source: Cancer Innovation. Feb2025, Vol. 4 Issue 1, p1-14. 14p.

Role of animal models in understanding the mechanisms of autoimmune diseases.

Authors: Khan, Wasif N. Lacoume, Grace M. Greidinger, Eric L.

Source: Autoimmunity. Dec2025, Vol. 58 Issue 1, p1-19. 19p.

Autoimmunity promotes chronic lymphocytic leukemia progression in an indolent disease model.

Authors: Pfeuffer, Lisa Siegert, Viola Trozzo, Riccardo et al.

Source: Scientific Reports. 2/3/2025, Vol. 15 Issue 1, p1-13. 13p.

Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways.

Authors: Langlois, Julie Lange, Simona Ebeling, Martin et al.

Source: Journal of Neuroinflammation. 10/27/2024, Vol. 21 Issue 1, p1-18. 18p.

Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study.

Authors: Gerhardt, Anke Dörfel, Steffen Schulz, Holger et al.

Source: European Journal of Haematology. Jun2024, Vol. 112 Issue 6, p927-937. 11p.

Restrained expansion of the recall germinal center response as biomarker of protection for influenza vaccination in mice.

Authors: Kil LP Vaneman J van der Lubbe JEM et al.

Source: PloS one [PLoS One] 2019 Nov 14; Vol. 14 (11), pp. e0225063. Date of Electronic Publication: 2019 Nov 14 (Print Publication: 2019).

Publication Type: Journal Article

Journal Info: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B‐cell lymphoma.

Authors: Daniel, Adrien Ghez, David Ravaiau, Camille et al.

Source: European Journal of Haematology. Dec2022, Vol. 109 Issue 6, p719-727. 9p.

Bruton's tyrosine kinase-bearing B cells and microglia in neuromyelitis optica spectrum disorder.

Authors: Liu, Ye Huang, Zhenning Zhang, Tian-Xiang et al.

Source: Journal of Neuroinflammation. 12/21/2023, Vol. 20 Issue 1, p1-20. 20p.

Transcription factor 12‐mediated self‐feedback regulatory mechanism is required in DUX4 fusion leukaemia.

Authors: Li, Zhihui Jiang, Minghao Wang, Junfei et al.

Source: Clinical & Translational Medicine. Dec2023, Vol. 13 Issue 12, p1-22. 22p.

Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling.

Authors: Batzilla, Alina Lu, Junyan Kivioja, Jarno et al.

Source: PLoS Computational Biology. 8/22/2022, Vol. 18 Issue 8, p1-19. 19p. 2 Diagrams, 2 Graphs.

MCIR1: A patient‐derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance.

Authors: Wu, Xiaosheng Nowakowski, Kevin E. Abeykoon, Jithma P. et al.

Source: European Journal of Haematology. Oct2021, Vol. 107 Issue 4, p458-465. 8p.

Unlocking potential inhibitors for Bruton's tyrosine kinase through in-silico drug repurposing strategies.

Authors: Alrouji, Mohammed Benjamin, Lizy Sonia Alhumaydhi, Fahad A. et al.

Source: Scientific Reports. 11/22/2023, Vol. 13 Issue 1, p1-12. 12p.

Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies.

Authors: Soberón V Osswald L Moore A et al.

Source: Leukemia [Leukemia] 2026 Mar; Vol. 40 (3), pp. 522-539. Date of Electronic Publication: 2026 Jan 16.

Publication Type: Journal Article

Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

Inhibition of head and neck squamous cell carcinoma by Bruton's tyrosine kinase inhibitor ibrutinib is associated with reduction of immunosuppressive T cells.

Authors: Bopp AR Lamenza FF Upadhaya P et al.

Source: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2025 May 30; Vol. 74 (7), pp. 227. Date of Electronic Publication: 2025 May 30.

Publication Type: Journal Article

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE

From development to clinical success: the journey of established and next-generation BTK inhibitors.

Authors: Gupta S Sharma A Shukla A et al.

Source: Investigational new drugs [Invest New Drugs] 2025 Apr; Vol. 43 (2), pp. 377-393. Date of Electronic Publication: 2025 Feb 27.

Publication Type: Journal Article; Review; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE

Targeting Bruton's tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study.

Authors: Guan, Wenxue Wang, Liang Peng, Xiaoyan

Source: Experimental Hematology & Oncology. 11/8/2022, Vol. 11 Issue 1, p1-5. 5p.

ALK-Positive Anaplastic Large-Cell Lymphoma in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review.

Authors: Yu, Qinchuan Zhao, Zhiqiang Wang, He et al.

Source: OncoTargets & Therapy. Oct2022, Vol. 15, p1245-1253. 9p.

Enhancing Fc‐mediated effector functions of monoclonal antibodies: The example of HexaBodies.

Authors: van der Horst, Hilma J. Mutis, Tuna

Source: Immunological Reviews. Nov2024, Vol. 328 Issue 1, p456-465. 10p.